Mirum reports 2024 net product sales $336.4M; guides 2025 sales $420M-$435M

Mirum Pharmaceuticals, Inc.

2024-FY EPS reported -$1.85 revenue$336,888,000

2024 net product sales $336.4M, up from $178.9M in 2023; LIVMARLI sales $213.3M, Bile Acid Medicines $123.1M.
2025 global net product sales guidance of $420M to $435M; expects positive cash flow.
Volixibat VISTAS PSC study expected to complete enrollment H2 2025; topline data in 2026.
Cash, equivalents and investments $292.8M as of Dec 31, 2024 (vs $286.3M end 2023).
CTEXLI (chenodiol) approved in US for cerebrotendinous xanthomatosis; MRM-3379 Phase 2 in FXS expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.